The American Heart Association convenes its annual Heart & Stroke Innovation Forum on Wednesday, April 20, 2016 at the Alexandria Center in New York City. Gathered leaders from industry and academia will explore how investment and innovation can accelerate advances to reduce heart disease and stroke risks – the #1 and #5 killers of men and women in the United States.
During the day, experts will take the platform in short “spark” sessions, panels and visual presentations to show how finance, regenerative medicine, smart tech and device advances can change patient mindsets, surgical staging and advance disruptive approaches to care. Some of our panelists include:
- Esther Dyson, Executive Founder, Way to Wellville
- JD Cassidy, Managing Director, Saatchi & Saatchi Wellness
- Adam Feinberg, PhD, Principal Investigator of the Regenerative Biomaterials and Therapeutics Group, Carnegie Mellon University
- Avner Halperin, CEO, EarlySense
- Jon Parks, CEO, CELF Tech
A special session, One Brave Idea!™ , will examine the American Heart Association’s newest venture in conjunction with Verily and AstraZeneca to provide $75 million in targeted funding to “Disrupt Cardiovascular Disease.”
The Heart and Stroke Innovation Forum is sponsored by BIOTRONIK, Inc., with additional support from Celf Technologies, Inc., EY, Regeneron and Royalty Pharma. Underwriting for the Forum is also acknowledged from Bristol-Myers Squibb, Sensible Medical Innovations, Caluent, EarlySense and contributions from DDG and Saatchi & Saatchi Wellness.
Our press release includes additional information on sessions and speakers.
For registration and program visit http://www.hsiforumnyc.heart.org.